CG Oncology, Inc. (NASDAQ:CGON) Stock Has Average Price Target of $87.50

Posted by Brian Himes on Nov 8th, 2026

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) has received a consensus rating of “Moderate Buy” from the ten analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $87.50.

CGON has been the topic of a number of research reports. Royal Bank Of Canada cut their target price on shares of CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of CG Oncology in a research report on Wednesday, July 29th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research note on Thursday, October 15th. Truist Financial upped their target price on CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Piper Sandler upped their target price on CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th.

View Our Latest Stock Analysis on CGON

Insider Buying and Selling

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $62.06, for a total value of $62,060.00. Following the completion of the transaction, the director owned 1,000 shares in the company, valued at $62,060. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 3,000 shares of company stock worth $209,580. Insiders own 4.80% of the company’s stock.

Institutional Trading of CG Oncology

Hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its holdings in shares of CG Oncology by 4.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,728 shares of the company’s stock worth $255,000 after purchasing an additional 175 shares during the last quarter. Covestor Ltd boosted its position in CG Oncology by 72.6% in the third quarter. Covestor Ltd now owns 770 shares of the company’s stock valued at $55,000 after buying an additional 324 shares in the last quarter. GAMMA Investing LLC boosted its position in CG Oncology by 47.9% in the third quarter. GAMMA Investing LLC now owns 1,081 shares of the company’s stock valued at $77,000 after buying an additional 350 shares in the last quarter. Fiduciary Financial Advisors bought a new position in shares of CG Oncology in the second quarter valued at approximately $28,000. Finally, NFSG Corp bought a new stake in CG Oncology during the 1st quarter worth approximately $34,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

CG Oncology Price Performance

NASDAQ CGON opened at $75.99 on Thursday. CG Oncology has a 1-year low of $35.80 and a 1-year high of $80.97. The firm has a market capitalization of $6.74 billion, a P/E ratio of -27.53 and a beta of 0.35. The business’s 50-day simple moving average is $68.23 and its 200-day simple moving average is $66.09.

CG Oncology (NASDAQ:CGON – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.19. The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.55 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. On average, equities research analysts expect that CG Oncology will post -3.31 EPS for the current fiscal year.

More CG Oncology News

Here are the key news stories impacting CG Oncology this week:

Positive Sentiment: CG Oncology reported a third-quarter loss of $0.64 per share, narrower than analysts’ estimates of about $0.83–$0.86 per share. Zacks earnings report
Positive Sentiment: Revenue was $1.6 million, above the approximately $0.55 million analysts expected, further supporting the favorable market reaction. CG Oncology Gains on Q3 Results
Neutral Sentiment: The quarterly loss widened from $0.57 per share a year earlier to $0.64, despite beating current estimates. Investors should weigh that ongoing loss against the earnings and revenue surprises. Zacks earnings report

About CG Oncology

(Get Free Report)

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biotechnology company focused on developing therapies for bladder cancer and other cancers affecting the urinary tract. The company is developing medicines designed to stimulate the immune system and target tumor cells within the bladder.

Its lead product candidate is cretostimogene grenadenorep, an investigational intravesical therapy based on an oncolytic adenovirus. The treatment is designed to be administered directly into the bladder, where it may selectively infect cancer cells, promote their destruction and activate an immune response against the tumor.